Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.952 EUR
−93.48 M EUR
698.35 K EUR
51.49 M
About CELLECTIS
Sector
CEO
André Choulika
Headquarters
Paris
Website
Founded
1999
ISIN
FR0010425595
FIGI
BBG000P78WZ9
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
1h long positionHi my friendt optimal next setup is hear for LONG good RR. Go on x2 or x5 good luck L.
cellectis alcls is going to rise heavilythis is how i see this asset
please refer to my higher time frame analysis for the global view
any comment is welcome
cellectis alcls : begenning of a new cycle
technicaly , it looks like the last phase of correction has ended, i.e the wave C( impulse with 5 waves)
fundamentaly , cellectis is growing big, has very good product, it's an awesome company
notice :
i'm not a financial adviser
i don't have anything to sell ( signal - education- etc..)
I only
Optimal incoming point for last 1 year with profit 500%Optimal incoming point for last 1 year with profit 500% What you mena my friends?
Bullish Looking for rejection off support/resistance line to resume bullish continuation and break through of the double top. Not a likely buy but a good one for the watchlists
CLLS Short IdeaAt significant points of resistance. Look for stock to begin to fall to past support.
$CLLS Breakout trade setup inCellectisEntry level $16 = Target price $19.50 = Stop loss $15
Significant break above 200ma.
Average analysts price target $37 | Buy rating
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ALCLS is 1.492 EUR — it has decreased by −0.40% in the past 24 hours. Watch CELLECTIS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange CELLECTIS stocks are traded under the ticker ALCLS.
ALCLS stock has fallen by −15.90% compared to the previous week, the month change is a −16.65% fall, over the last year CELLECTIS has showed a −54.09% decrease.
We've gathered analysts' opinions on CELLECTIS future price: according to them, ALCLS price has a max estimate of 9.17 EUR and a min estimate of 2.75 EUR. Watch ALCLS chart and read a more detailed CELLECTIS stock forecast: see what analysts think of CELLECTIS and suggest that you do with its stocks.
ALCLS reached its all-time high on Nov 6, 2015 with the price of 41.950 EUR, and its all-time low was 0.888 EUR and was reached on Oct 27, 2023. View more price dynamics on ALCLS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ALCLS stock is 3.83% volatile and has beta coefficient of 1.17. Track CELLECTIS stock price on the chart and check out the list of the most volatile stocks — is CELLECTIS there?
Today CELLECTIS has the market capitalization of 107.56 M, it has decreased by −14.09% over the last week.
Yes, you can track CELLECTIS financials in yearly and quarterly reports right on TradingView.
CELLECTIS is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ALCLS earnings for the last quarter are −0.21 EUR per share, whereas the estimation was −0.22 EUR resulting in a 3.09% surprise. The estimated earnings for the next quarter are −0.17 EUR per share. See more details about CELLECTIS earnings.
CELLECTIS revenue for the last quarter amounts to 16.56 M EUR, despite the estimated figure of 4.94 M EUR. In the next quarter, revenue is expected to reach 9.04 M EUR.
ALCLS net income for the last quarter is −20.99 M EUR, while the quarter before that showed −23.47 M EUR of net income which accounts for 10.59% change. Track more CELLECTIS financial stats to get the full picture.
No, ALCLS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 221.00 employees. See our rating of the largest employees — is CELLECTIS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CELLECTIS EBITDA is −65.90 M EUR, and current EBITDA margin is −11.67 K%. See more stats in CELLECTIS financial statements.
Like other stocks, ALCLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELLECTIS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CELLECTIS technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CELLECTIS stock shows the sell signal. See more of CELLECTIS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.